C3L-00973
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 76.10677618
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- TGF_BETA_SIGNALING+0.530
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.380
- KRAS_SIGNALING_UP+0.310
- COMPLEMENT+0.300
- NOTCH_SIGNALING+0.300
- IL6_JAK_STAT3_SIGNALING+0.290
- IL2_STAT5_SIGNALING+0.280
- PROTEIN_SECRETION+0.270
Top 10 suppressed
- E2F_TARGETS-0.500
- MYC_TARGETS_V2-0.480
- G2M_CHECKPOINT-0.460
- MTORC1_SIGNALING-0.330
- CHOLESTEROL_HOMEOSTASIS-0.300
- SPERMATOGENESIS-0.300
- MYC_TARGETS_V1-0.290
- FATTY_ACID_METABOLISM-0.250
- UV_RESPONSE_UP-0.170
- KRAS_SIGNALING_DN-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.852 |
| 2 | MNG416 | — | — | 0.850 |
| 3 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.848 |
| 4 | TCGA-OR-A5JI-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.847 |
| 5 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.842 |
| 6 | TCGA-E2-A1L9-01A-11R-A13Q-07 | — | A | 0.841 |
| 7 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.837 |
| 8 | SRR8613789 | — | A | 0.837 |
| 9 | SRR5088910 | — | — | 0.831 |
| 10 | SRR8613773 | — | A | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |